Stocktoria
Kiniksa Pharmaceuticals International, plc KNSA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-05-24
Kiniksa Pharmaceuticals International, plc statistics & valuation
Market cap$4.6B
P / E77.2×
P / S6.7×
P / B8.0×
P / FCF33.4×
Net margin8.7%
Return on equity10.4%
FCF margin20.1%
Return on capital12.4%
Graham number -85.9%$11.01
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($11.01); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating margin | 11.4% | -10.8% | -9.3% | 4.4% | -406.4% | — | — | — | — |
| Net margin | 8.7% | -10.2% | 5.2% | 83.3% | -409.7% | — | — | — | — |
| FCF margin | 20.1% | 6.0% | 4.9% | 2.6% | -328.7% | — | — | — | — |
| Return on assets | 7.7% | -7.4% | 2.7% | 39.9% | -67.8% | -46.2% | -63.6% | -32.1% | -136.6% |
| Return on equity | 10.4% | -9.9% | 3.2% | 46.3% | -85.3% | -51.7% | -71.8% | -37.0% | 72.3% |
| Current ratio | 3.79 | 3.30 | 4.34 | 5.16 | 4.38 | 10.46 | 8.68 | 7.37 | 2.70 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.